Ominoz-D Capsule SR contains a combination of Domperidone 30 mg and Esomeprazole 40 mg, formulated to provide sustained relief from gastrointestinal disorders. Domperidone is a dopamine antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, effectively reducing acid-related damage to the esophageal and gastric mucosa. This combination is particularly useful in managing conditions such as gastroesophageal reflux disease (GERD), dyspepsia, and gastroparesis, where both acid suppression and improved motility are required. Ominoz-D Capsule SR’s sustained-release formulation ensures prolonged therapeutic effects, enhancing patient compliance by reducing dosing frequency. It is recommended to be taken as directed by a healthcare professional, typically before meals. Caution is advised in patients with known hypersensitivity to either component, and it should be used with care in individuals with hepatic or renal impairment. Common adverse effects may include headache, dry mouth, or gastrointestinal disturbances. Consultation with a physician is essential before initiating therapy to ensure appropriate use and monitoring.